Jazz Pharmaceuticals plc last reported quarterly results on Oct 26, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $1.2 billion (+10.4% year over year) and diluted EPS of -$7.48. It usually reports 12–35 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–35 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 26, 2026
26 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
1,243
+10.4%
|
-483
-292.3%
|
-7.48
-283.3%
|
|
Aug 3, 2026
34 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
1,208
+15.5%
|
193
+126.8%
|
2.78
+123.7%
|
|
May 5, 2026
35 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
1,069
+19.1%
|
293
+416.9%
|
4.43
+391.4%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
1,198
+10.1%
|
203
+6.5%
|
3.34
+7.5%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
1,126
+6.7%
|
251
+16.9%
|
4.08
+19.3%
|
|
Aug 5, 2025
36 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
1,046
+2.1%
|
-718
-526.2%
|
-11.74
-571.5%
|
|
May 6, 2025
36 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
898
-0.5%
|
-92
-532.8%
|
-1.52
-560.9%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
1,088
+7.5%
|
191
+103.0%
|
3.11
+129.9%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JAZZ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Ireland
- Headquarters
- Dublin
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1232524
- Former names
- JAZZ PHARMACEUTICALS INC (until Jan 18, 2012)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.